|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.19 USD | -0.73% |
|
-29.29% | +78.74% |
| May. 08 | Transcript : Y-mAbs Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
| May. 07 | Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q1 Revenue $19.9M, vs. Street Est of $22.2M | MT |
Dec 1 (Reuters) -
The U.S. Food and Drug Administration on Thursday declined to approve a treatment from Y-mAbs Therapeutics for a rare form of nerve cancer in pediatric patients, dragging its shares 15% lower in extended trade. (Reporting by Aditya Samal and Leroy Leo in Bengaluru; Editing by Sriraj Kalluvila)
| 1st Jan change | Capi. | |
|---|---|---|
| +78.74% | 535M | |
| +5.66% | 111B | |
| +11.23% | 105B | |
| -2.18% | 21.93B | |
| -12.15% | 22.34B | |
| -5.52% | 18.59B | |
| -36.52% | 18.12B | |
| -10.09% | 16.96B | |
| +3.33% | 13.7B | |
| +36.58% | 12.45B |
Y-MABS THERAPEUTICS, INC. 